Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 18:18 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 3CompletedINTERVENTIONAL

Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients

ClinicalTrials.gov · NCT00210457 · Registry updated: 2020-03-31

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: France · Switzerland
Registry dates and results: Start: 2000-09. Completion: 2002-07-15 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (Autogel formulation) (drug)

Where the study takes place — 17 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Hôpital Sud
Amiens, France
Site recruitment: Not reported
Chu d'Angers
Angers, France
Site recruitment: Not reported
Hôpital de Bois Guillaume
Bois-Guillaume, France
Site recruitment: Not reported
Chu de la Cote de Nacre
Caen, France
Site recruitment: Not reported
Hôpital du Bocage
Dijon, France
Site recruitment: Not reported
Chu de Bicêtre
Le Kremlin-Bicêtre, France
Site recruitment: Not reported
Hôpital du Cluzeau
Limoges, France
Site recruitment: Not reported
Hôpital Neurologique
Lyon, France
Site recruitment: Not reported
Hôpital Lapeyronie
Montpellier, France
Site recruitment: Not reported
Hôpital de l'Archet 1
Nice, France
Site recruitment: Not reported
Hôpital du Haut-Levêque
Pessac, France
Site recruitment: Not reported
Hôpital Maison Blanche
Reims, France
Site recruitment: Not reported
Hôpital Sud
Rennes, France
Site recruitment: Not reported
Hôpital Bellevue
Saint-Etienne, France
Site recruitment: Not reported
Hôpital de Hautepierre
Strasbourg, France
Site recruitment: Not reported
Hôpital de Rangueil
Toulouse, France
Site recruitment: Not reported
Centre Hospitalier Vaudois
Lausanne, Switzerland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3WithdrawnINTERVENTIONAL

Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome

ClinicalTrials.gov · NCT04065165 · Registry updated: 2020-02-05

Condition / research focus: Small Intestinal NET; Carcinoid Heart Disease
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Countries with listed sites: No country reported
Registry dates and results: Start: 2020-04. Completion: 2027-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Telotristat Ethyl (drug) — also listed as: Xermelo
Lanreotide (drug) — also listed as: Somatuline

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Microbiotic Analysis in Digestive Endocrine Tumors

ClinicalTrials.gov · NCT04198402 · Registry updated: 2019-12-13

Condition / research focus: Digestive Neuroendocrine Tumor; Fecal Microbiota; Bacterial Signature
Sponsor: Assistance Publique - Hôpitaux de Paris
Countries with listed sites: No country reported
Registry dates and results: Start: 2020-01. Completion: 2023-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Biological sampling (biological)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Somatuline Autogel Preference and Health Economy Study

ClinicalTrials.gov · NCT00681187 · Registry updated: 2019-11-22

Condition / research focus: Neuroendocrine Tumour With Carcinoid Symptoms
Sponsor: Ipsen
Countries with listed sites: Denmark · Norway · Sweden
Registry dates and results: Start: 2008-06. Completion: 2010-08 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

lanreotide (Autogel formulation) (drug)

Where the study takes place — 10 listed sites

Aarhus University Hospital / Medisinsk afd. V
Aarhus, Denmark
Site recruitment: Not reported
Odense Univeristy Hospital / S-AMB
Odense, Denmark
Site recruitment: Not reported
Haukeland University Hospital / Kreftafd
Bergen, Norway
Site recruitment: Not reported
University Hospital North-Norway / GastroLab
Tromsø, Norway
Site recruitment: Not reported
S:t Olavs Hospital / Medisinsk Afd
Trondheim, Norway
Site recruitment: Not reported
Sahlgrenska University Hospital / Kirurgkliniken
Gothenburg, Sweden
Site recruitment: Not reported
Linköping University Hospital / Onkologen
Linköping, Sweden
Site recruitment: Not reported
Karolinska University Hospital, Huddinge / GastroCentrum Medicin
Stockholm, Sweden
Site recruitment: Not reported
Karolinska University Hospital, Solna / Kirurgmottagningen
Stockholm, Sweden
Site recruitment: Not reported
Akademiska Hospital/ Kliniken f onkologisk endokrinologi
Uppsala, Sweden
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3TerminatedINTERVENTIONAL

Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients

ClinicalTrials.gov · NCT01313273 · Registry updated: 2019-11-22

Condition / research focus: Prostate Cancer
Sponsor: Ipsen
Countries with listed sites: Italy
Registry dates and results: Start: 2011-06. Completion: 2013-06 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide, non steroidal anti androgens and LHRH-a (drug)
Non steroidal anti androgens and LHRH-a (drug)

Where the study takes place — 1 listed sites

A.O. S. Luigi Gonzaga
Orbassano ( TO), Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

Quality of Life in Patients With Inoperable Malignant Bowel Obstruction

ClinicalTrials.gov · NCT02365584 · Registry updated: 2019-11-22

Condition / research focus: Intestinal Obstruction
Sponsor: Ipsen
Countries with listed sites: Italy
Registry dates and results: Start: 2015-01. Completion: 2018-01-16 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

lanreotide (Autogel formulation) (drug)

Where the study takes place — 13 listed sites

Ospedale Sacro Cuore di Gesù, U.O.C. Oncologia Medica
Gallipoli, Lecce, Italy
Site recruitment: Not reported
Ospedali riuniti Ancona- Dipartimento Medicina Interna - Clinica Oncologica
Ancona, Italy
Site recruitment: Not reported
Centro di Riferimento Oncologico - di Aviano, Dip. di Oncologia Chirurgica- S.O.C. di Chirurgia Oncologica Generale
Aviano, Italy
Site recruitment: Not reported
Istituto Tumori "Giovanni Paolo II"- Istituto di Ricovero e Cura a Carattere Scientifico, U.O.C. DI ONCOLOGIA MEDICA
Bari, Italy
Site recruitment: Not reported
Ospedale Sacro Cuore di Gesù - Fatebenefratelli
Benevento, Italy
Site recruitment: Not reported
Hospice Convento delle Oblate
Florence, Italy
Site recruitment: Not reported
Azienda Sanitaria Locale n ° 5 "Spezzino" Ospedale Felettino - Oncologia Via del Forno 4
La Spezia, Italy
Site recruitment: Not reported
I.R.C.C.S. Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori (I.R.S.T.) srl
Meldola, Italy
Site recruitment: Not reported
Ospedale San Raffaele IRCCS, Ginecologia oncologica
Milan, Italy
Site recruitment: Not reported
Fondazione IRCCS Istituto Nazionale dei Tumori - Struttura Complessa di Cure Palliative, Terapia del Dolore e Riabilitazione
Milan, Italy
Site recruitment: Not reported
Azienda Ospedaliero - Polo Universitario "Luigi Sacco"
Milan, Italy
Site recruitment: Not reported
A.R.N.A.S. P.O. Civico Benfratelli - Oncologia Medica
Palermo, Italy
Site recruitment: Not reported
Azienda Ospedaliera Regionale San Carlo- Oncologia Medica
Potenza, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly

ClinicalTrials.gov · NCT00444873 · Registry updated: 2019-11-22

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: Germany
Registry dates and results: Start: 2005-01. Completion: 2008-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval (drug)

Where the study takes place — 1 listed sites

Klinikum Innenstadt
Munich, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

ClinicalTrials.gov · NCT00216398 · Registry updated: 2019-08-16

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: Australia
Registry dates and results: Start: 2004-06. Completion: 2006-06-22 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (Autogel formulation) (drug)

Where the study takes place — 1 listed sites

Westmead Hospital
Westmead, New South Wales, Australia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Somatuline Autogel: Acromegaly Self/Partner Injection Study

ClinicalTrials.gov · NCT00149188 · Registry updated: 2019-08-05

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2004-02. Completion: 2005-08-24 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (Autogel formulation) (drug)

Where the study takes place — 10 listed sites

Michael White Centre Diabetes & Endocrinology, Hull Royal Infirmary
Hull, East Yorkshire, United Kingdom
Site recruitment: Not reported
Department of Endocrinology, The Royal Free Hospital
Hampstead, London, United Kingdom
Site recruitment: Not reported
Dept of Endocrinology, Aberdeen Royal Infirmary
Aberdeen, United Kingdom
Site recruitment: Not reported
Department of Medicine, Queen Elizabeth Hospital
Birmingham, United Kingdom
Site recruitment: Not reported
Department of Endocrinology, Coventry & Warwickshire Hospital
Coventry, United Kingdom
Site recruitment: Not reported
Department of Endocrinology, Leicester Royal Infirmary
Leicester, United Kingdom
Site recruitment: Not reported
Department of Endocrinology, Manchester Royal Infirmary
Manchester, United Kingdom
Site recruitment: Not reported
The Oxford Centre for Diabetes, Endocrinology and Metabolism, The Churcill Hospital
Oxford, United Kingdom
Site recruitment: Not reported
Department of Endocrinology, Royal Hallamshire Hospital
Sheffield, United Kingdom
Site recruitment: Not reported
Department of Endocrinology, Sunderland Royal Hospital
Sunderland, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2WithdrawnINTERVENTIONAL

Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)

ClinicalTrials.gov · NCT00517491 · Registry updated: 2019-08-05

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: Mexico
Registry dates and results: Start: 2008-05. Completion: 2008-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

lanreotide (Autogel formulation) (drug)

Where the study takes place — 1 listed sites

Centro Médico Nacional Siglo XXI, IMSS
Mexico City, Mexico
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects

ClinicalTrials.gov · NCT02807233 · Registry updated: 2019-08-05

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: Portugal · Spain
Registry dates and results: Start: 2016-07. Completion: 2017-09 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 39 listed sites

Hospital de Santa Maria
Lisbon, Portugal
Site recruitment: Not reported
Centro Hospitalar Sao Jöao
Porto, Portugal
Site recruitment: Not reported
Hospital Univ. Nuestra Sra. Candelaria
Santa Cruz, Tenerife, Spain
Site recruitment: Not reported
Complejo Hospitalario Univ. A Coruña
A Coruña, Spain
Site recruitment: Not reported
Hospital Univ. Príncipe de Asturias
Alcalá de Henares, Spain
Site recruitment: Not reported
Hospital General Univ. de Alicante
Alicante, Spain
Site recruitment: Not reported
Hospital Univ. La Ribera
Alzira, Spain
Site recruitment: Not reported
Hospital Infanta Cristina
Badajoz, Spain
Site recruitment: Not reported
Hospital Cruces
Barakaldo, Spain
Site recruitment: Not reported
Hospital Puerta del Mar
Cadiz, Spain
Site recruitment: Not reported
Hospital Ciudad Real
Ciudad Real, Spain
Site recruitment: Not reported
Hospital Reina Sofía
Córdoba, Spain
Site recruitment: Not reported
Hospital de Getafe
Getafe, Spain
Site recruitment: Not reported
Hospital Univ. Girona Dr. Josep Trueta
Girona, Spain
Site recruitment: Not reported
Hospital de Jaén
Jaén, Spain
Site recruitment: Not reported
Hospital Bellvitge
L'Hospitalet de Llobregat, Spain
Site recruitment: Not reported
Hospital Univ. León
León, Spain
Site recruitment: Not reported
Hospital Arnau de Vilanova
Lleida, Spain
Site recruitment: Not reported
Hospital La Princesa
Madrid, Spain
Site recruitment: Not reported
Hospital Gregorio Marañón
Madrid, Spain
Site recruitment: Not reported
Hospital La Paz
Madrid, Spain
Site recruitment: Not reported
Hospital Univv. La Paz
Madrid, Spain
Site recruitment: Not reported
Hospital Puerta del Hierro
Madrid, Spain
Site recruitment: Not reported
Hospital Civil de Málaga
Málaga, Spain
Site recruitment: Not reported
Hospital Virgen de la Victoria
Málaga, Spain
Site recruitment: Not reported
Hospital Univ. Central de Asturias
Oviedo, Spain
Site recruitment: Not reported
Hospital Univ. Son Espases
Palma, Spain
Site recruitment: Not reported
Corporacio Sanitaria Parc Tauli
Sabadell, Spain
Site recruitment: Not reported
Hospital Infanta Sofía
San Sebastián de los Reyes, Spain
Site recruitment: Not reported
Hospital Clínico Univ. Santiago
Santiago de Compostela, Spain
Site recruitment: Not reported
Hospital Virgen del Rocío
Seville, Spain
Site recruitment: Not reported
Hospital Univ. Alava
Terrassa, Spain
Site recruitment: Not reported
Hospital Univ. Mutua de Terrassa
Terrassa, Spain
Site recruitment: Not reported
Hospital Obispo Polanco
Teruel, Spain
Site recruitment: Not reported
Hospital Virgen de la Salud
Toledo, Spain
Site recruitment: Not reported
Hospital Clínico de Valencia
Valencia, Spain
Site recruitment: Not reported
Hospital Univ. La Fe
Valencia, Spain
Site recruitment: Not reported
Hospital Clínico Univ. Valladolid
Valladolid, Spain
Site recruitment: Not reported
Hospital Miguel Servet
Zaragoza, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3CompletedINTERVENTIONAL

Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly

ClinicalTrials.gov · NCT00234572 · Registry updated: 2019-08-02

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: Czechia · France · Germany · Hong Kong · Hungary · Netherlands · United Kingdom · United States
Registry dates and results: Start: 2000-05. Completion: 2003-01-03 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (Autogel formulation) (drug)

Where the study takes place — 29 listed sites

Baptist Health System Inc
Birmingham, Alabama, United States
Site recruitment: Not reported
Pituitary Center
Los Angeles, California, United States
Site recruitment: Not reported
Northwestern Medical Facility
Chicago, Illinois, United States
Site recruitment: Not reported
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
Site recruitment: Not reported
Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported
University of Michigan Medical Center
Ann Arbor, Michigan, United States
Site recruitment: Not reported
New York University Medical Center
New York, New York, United States
Site recruitment: Not reported
University of Cincinnati
Cincinnati, Ohio, United States
Site recruitment: Not reported
Oregon Health Sciences University
Portland, Oregon, United States
Site recruitment: Not reported
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Ben Taub Hospital
Houston, Texas, United States
Site recruitment: Not reported
St Ann's Faculty Hospital
Brno, Czechia
Site recruitment: Not reported
University Hospital Charles University
Hradec Králové, Czechia
Site recruitment: Not reported
Charles University
Prague, Czechia
Site recruitment: Not reported
Clinique Marc Linquette
Lille, France
Site recruitment: Not reported
Hôpital Lariboisière - Service de Médecine B
Paris, France
Site recruitment: Not reported
Hôpital Cochin - Service d'Endocrinologie
Paris, France
Site recruitment: Not reported
CHRU de Brabois
Vandœuvre-lès-Nancy, France
Site recruitment: Not reported
Universitätklinikum Charité
Berlin, Germany
Site recruitment: Not reported
Med. Klinik der Universitätat Essen
Essen, Germany
Site recruitment: Not reported
Medizinische Klinik Innenstadt
München, Germany
Site recruitment: Not reported
Queen Mary Hospital
Pokfulam, Hong Kong
Site recruitment: Not reported
Semmelweiss University Medical School
Budapest, Hungary
Site recruitment: Not reported
Semmelweiss University
Budapest, Hungary
Site recruitment: Not reported
Academic Hospital Leiden
Leiden, Netherlands
Site recruitment: Not reported
Academic Hospital Rotterdam
Rotterdam, Netherlands
Site recruitment: Not reported
Queen Elizabeth Hospital
Edgbaston, Birmingham, United Kingdom
Site recruitment: Not reported
The Royal Free Hospital
Hampstead, London, United Kingdom
Site recruitment: Not reported
Christie Hospital
Manchester, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide

ClinicalTrials.gov · NCT00234520 · Registry updated: 2019-08-02

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: Belgium · Czechia · Denmark · France · Hungary · Italy · Poland · Spain · Sweden · United Kingdom
Registry dates and results: Start: 2003-05. Completion: 2005-02-18 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 33 listed sites

Cliniques Universitaires Saint Luc
Brussels, Belgium
Site recruitment: Not reported
UZ Gasthuisberg
Leuven, Belgium
Site recruitment: Not reported
CHU de Liege
Liège, Belgium
Site recruitment: Not reported
University Hospital, Charles University
Kralove, Czechia
Site recruitment: Not reported
1st School of Medicine, Charles University
Prague, Czechia
Site recruitment: Not reported
National University Hospital
Copenhagen, Denmark
Site recruitment: Not reported
Hôpital de Bois
Bois-Guillaume, France
Site recruitment: Not reported
Hôpital de la Timone
Marseille, France
Site recruitment: Not reported
CHU de Brabois
Nancy, France
Site recruitment: Not reported
Centre Hospitalier Régional d'Orléans
Orléans, France
Site recruitment: Not reported
Hôpital du Haut-Lévêque
Pessac, France
Site recruitment: Not reported
Hôpital Maison Blanche
Reims, France
Site recruitment: Not reported
CHU de Rangueil
Toulouse, France
Site recruitment: Not reported
Semmelweis University Medical School
Budapest, Hungary
Site recruitment: Not reported
National Medical Center
Budapest, Hungary
Site recruitment: Not reported
Ospedali Riuniti di Bergamo
Bergamo, Italy
Site recruitment: Not reported
Università degli Studi di Ferrara
Ferrara, Italy
Site recruitment: Not reported
Dipartimento di Scienze, Endocrinologiche e Metaboliche
Genova, Italy
Site recruitment: Not reported
Università degli Studi di Milano
Milan, Italy
Site recruitment: Not reported
University "Federico II" of Naples
Naples, Italy
Site recruitment: Not reported
Clinica Medica II
Roma, Italy
Site recruitment: Not reported
Bielanski Hospital
Warsaw, Poland
Site recruitment: Not reported
Hospital General de Alicante
Alicante, Spain
Site recruitment: Not reported
Clínica Puerta de Hierro
Madrid, Spain
Site recruitment: Not reported
Fundación Jiménez Díaz
Madrid, Spain
Site recruitment: Not reported
Research Centre for Endocrinology and Metabolism
Gothenburg, Sweden
Site recruitment: Not reported
Endokrinologiska kliniken
Malmö, Sweden
Site recruitment: Not reported
Karolinska Sjukhuset
Stockholm, Sweden
Site recruitment: Not reported
Queen Elizabeth Medical Centre
Edgbaston, Birmingham, United Kingdom
Site recruitment: Not reported
Royal Free Hospital
Hampstead, United Kingdom
Site recruitment: Not reported
Michael White Diabetes Centre
Hull, United Kingdom
Site recruitment: Not reported
Christie Hospital
Manchester, United Kingdom
Site recruitment: Not reported
Northern General Hospital
Sheffield, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients

ClinicalTrials.gov · NCT02075606 · Registry updated: 2019-06-07

Condition / research focus: NeuroEndocrine Tumours
Sponsor: Ipsen
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2014-05. Completion: 2017-06 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

lanreotide acetate (drug)

Where the study takes place — 14 listed sites

Basingstoke & North Hampshire Hospital
Basingstoke, United Kingdom
Site recruitment: Not reported
Queen Elizabeth Hospital
Birmingham, United Kingdom
Site recruitment: Not reported
University Hospital Wales
Cardiff, United Kingdom
Site recruitment: Not reported
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
Site recruitment: Not reported
St James's University Hospital
Leeds, United Kingdom
Site recruitment: Not reported
University Hospital Aintree
Liverpool, United Kingdom
Site recruitment: Not reported
Hammersmith Hospital
London, United Kingdom
Site recruitment: Not reported
King's College Hospital
London, United Kingdom
Site recruitment: Not reported
Royal Free Hospital
London, United Kingdom
Site recruitment: Not reported
Maidstone Hospital
Maidstone, United Kingdom
Site recruitment: Not reported
The Christie Hospital
Manchester, United Kingdom
Site recruitment: Not reported
Norfolk & Norwich Hospital
Norwich, United Kingdom
Site recruitment: Not reported
Royal Hallamshire Hospital
Sheffield, United Kingdom
Site recruitment: Not reported
Southampton University Hospital
Southampton, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET

ClinicalTrials.gov · NCT03083210 · Registry updated: 2019-05-20

Condition / research focus: Neuroendocrine Tumors
Sponsor: Samsung Medical Center
Countries with listed sites: South Korea
Registry dates and results: Start: 2017-07-05. Completion: 2020-02 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (drug)

Where the study takes place — 1 listed sites

Youngsuk Park
Seoul, South Korea
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET

ClinicalTrials.gov · NCT02231762 · Registry updated: 2019-05-06

Condition / research focus: Gastroenteropancreatic Neuroendocrine Tumors
Sponsor: Ipsen
Countries with listed sites: Austria · Germany
Registry dates and results: Start: 2014-10. Completion: 2017-06 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide Autogel 120 mg (drug)
Temozolomide (TMZ) (drug)

Where the study takes place — 10 listed sites

Vienna General Hospital
Vienna, Austria
Site recruitment: Not reported
Zentralklinik Bad Berka
Bad Berka, Germany
Site recruitment: Not reported
Charité University Hospital
Berlin, Germany
Site recruitment: Not reported
University Hospital Essen
Essen, Germany
Site recruitment: Not reported
ENDOC Hamburg
Hamburg, Germany
Site recruitment: Not reported
Oncological Center Leer
Leer, Germany
Site recruitment: Not reported
University Hospital Mainz
Mainz, Germany
Site recruitment: Not reported
University Hospital Mannheim
Mannheim, Germany
Site recruitment: Not reported
University Hospital Marburg
Marburg, Germany
Site recruitment: Not reported
University Hospital Munich
Munich, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

ClinicalTrials.gov · NCT02396953 · Registry updated: 2019-04-25

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: Belgium · Czechia · France · Germany · Italy · Lithuania · Netherlands · Poland · Romania · Russia · Spain · United Kingdom
Registry dates and results: Start: 2015-03. Completion: 2017-11-28 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide PRF (drug) — also listed as: Lanreotide acetate

Where the study takes place — 36 listed sites

Antwerp University Hospital
Edegem, Belgium
Site recruitment: Not reported
Domaine Universitaire Sart Tilman
Liège, Belgium
Site recruitment: Not reported
Fakultni nemocnice u sv. Anny v Brne
Brno, Czechia
Site recruitment: Not reported
Fakultní nemocnice Hradec Králové (University Hospital Hradec)
Hradec Králové, Czechia
Site recruitment: Not reported
CHU le BOCAGE
Dijon, France
Site recruitment: Not reported
Hôpital de Bicêtre (AP-HP)
Le Kremlin-Bicêtre, France
Site recruitment: Not reported
CHU de la Timone
Marseille, France
Site recruitment: Not reported
Hôpital Haut Lévêque
Pessac, France
Site recruitment: Not reported
University Medicine Berlin
Berlin, Germany
Site recruitment: Not reported
University Medical Center Hamburg-Eppendorf
Hamburg, Germany
Site recruitment: Not reported
IRCCS AOU San Martino-IST, University of Genova
Genova, Italy
Site recruitment: Not reported
Azienda Ospedaliera Padova
Padova, Italy
Site recruitment: Not reported
Policlinico of Palermo
Palermo, Italy
Site recruitment: Not reported
Ospedale Cisanello
Pisa, Italy
Site recruitment: Not reported
Azienda Ospedaliera Universitaria Senese
Siena, Italy
Site recruitment: Not reported
AO Città della Salute e della Scienza di Torino
Torino, Italy
Site recruitment: Not reported
Lithuanian University of Health Sciences (LUHS) Kauno klinikos
Kaunas, Lithuania
Site recruitment: Not reported
Vilnius University hospital Santariskiu Klinikos
Vilnius, Lithuania
Site recruitment: Not reported
Erasmus University Medical Centre Rotterdam
Rotterdam, Netherlands
Site recruitment: Not reported
Uniwersytecki Szpital Kliniczny w Białymstoku
Bialystok, Poland
Site recruitment: Not reported
Szpital Kliniczny im. H. Święcickiego UM w Poznaniu
Poznan, Poland
Site recruitment: Not reported
Szpital Bielanski im. ks. Jerzego Popieluszki SPZOZ
Warsaw, Poland
Site recruitment: Not reported
Szpital Kliniczny nr 1
Wroclaw, Poland
Site recruitment: Not reported
National Institute of Endocrinology
Bucharest, Romania
Site recruitment: Not reported
Kazan state Medical Academy
Kazan', Russia
Site recruitment: Not reported
Kemerovo Regional Clinical Hospital
Kemerovo, Russia
Site recruitment: Not reported
Endocrinological Research Center Ministry of Health Russian Federation
Moscow, Russia
Site recruitment: Not reported
Healthcare Institution
Nizhny Novgorod, Russia
Site recruitment: Not reported
Federal State Budgetary Military
Saint Petersburg, Russia
Site recruitment: Not reported
North-Western State Medical University
Saint Petersburg, Russia
Site recruitment: Not reported
Hospital Universitario Vall d' Hebron
Barcelona, Spain
Site recruitment: Not reported
Hospital Ramon y Cajal
Madrid, Spain
Site recruitment: Not reported
Hospital Universitario Virgen del Rocio
Seville, Spain
Site recruitment: Not reported
Queen Mary, University of London
London, United Kingdom
Site recruitment: Not reported
Christie NHS Foundation Trust
Manchester, United Kingdom
Site recruitment: Not reported
Churchill Hospital
Oxford, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction

ClinicalTrials.gov · NCT02275338 · Registry updated: 2019-04-16

Condition / research focus: Intestinal Obstruction
Sponsor: Ipsen
Countries with listed sites: Belgium
Registry dates and results: Start: 2014-11-19. Completion: 2017-11-09 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide Autogel (drug) — also listed as: Somatuline Autogel

Where the study takes place — 17 listed sites

Facility not reported
Aalst, Belgium
Site recruitment: Not reported
Facility not reported
Antwerp, Belgium
Site recruitment: Not reported
Facility not reported
Bruges, Belgium
Site recruitment: Not reported
Ste-Elisabeth Hospital
Brussels, Belgium
Site recruitment: Not reported
Facility not reported
Chimay, Belgium
Site recruitment: Not reported
Facility not reported
Ghent, Belgium
Site recruitment: Not reported
Facility not reported
Haine-Saint-Paul, Belgium
Site recruitment: Not reported
Facility not reported
Libramont, Belgium
Site recruitment: Not reported
Facility not reported
Liège, Belgium
Site recruitment: Not reported
Facility not reported
Mons, Belgium
Site recruitment: Not reported
Facility not reported
Montigny-le-Tilleul, Belgium
Site recruitment: Not reported
Facility not reported
Ostend, Belgium
Site recruitment: Not reported
Facility not reported
Ottignies, Belgium
Site recruitment: Not reported
Facility not reported
Sint-Niklaas, Belgium
Site recruitment: Not reported
Facility not reported
Tournai, Belgium
Site recruitment: Not reported
Facility not reported
Verviers, Belgium
Site recruitment: Not reported
Facility not reported
Yvoir, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae

ClinicalTrials.gov · NCT00729313 · Registry updated: 2019-03-04

Condition / research focus: Digestive Fistulae
Sponsor: Ipsen
Countries with listed sites: France · Russia
Registry dates and results: Start: 2000-04. Completion: 2005-04 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide microparticles (drug)
Placebo (drug)

Where the study takes place — 19 listed sites

Hôpital Nord
Amiens, France
Site recruitment: Not reported
CHU J. Minjoz
Besançon, France
Site recruitment: Not reported
Hôpital Avicenne
Bobigny, France
Site recruitment: Not reported
Hôpital de la Cavale Blanche
Brest, France
Site recruitment: Not reported
Hôpital Louis Mourier
Colombes, France
Site recruitment: Not reported
Hôpital Henri Mondor
Créteil, France
Site recruitment: Not reported
Hôpital A. Michallon
Grenoble, France
Site recruitment: Not reported
CHU de Bicêtre
Le Kremlin-Bicêtre, France
Site recruitment: Not reported
Hôpital Edouard Herriot
Lyon, France
Site recruitment: Not reported
Hotel Dieu
Lyon, France
Site recruitment: Not reported
Hôpital Nord
Marseille, France
Site recruitment: Not reported
Hôpital Lariboisière
Paris, France
Site recruitment: Not reported
Groupe Hospitalier Pitié-Salpêtrière
Paris, France
Site recruitment: Not reported
Hôpital Pontchaillou
Rennes, France
Site recruitment: Not reported
Hôpital de Hautepierre
Strasbourg, France
Site recruitment: Not reported
Hôpital Trousseau
Tours, France
Site recruitment: Not reported
Hôpital de Brabois
Vandœuvre-lès-Nancy, France
Site recruitment: Not reported
Institute of Surgery n.a. A.V. Vishnevsky
Moscow, Russia
Site recruitment: Not reported
National Research Centre of Surgery
Moscow, Russia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly

ClinicalTrials.gov · NCT02493517 · Registry updated: 2019-01-29

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: China
Registry dates and results: Start: 2014-10. Completion: 2017-02-16 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide Autogel® (drug)
Lanreotide Acetate (drug)

Where the study takes place — 10 listed sites

Peking Union Medical College Hospital
Beijing, China
Site recruitment: Not reported
West China Hospital, Sichuan University
Chengdu, China
Site recruitment: Not reported
Fujian Provincial Hospital
Fuzhou, China
Site recruitment: Not reported
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, China
Site recruitment: Not reported
Affiliate Hospital of Guiyang Medical College
Guizhou, China
Site recruitment: Not reported
Jiangsu Provincial People's Hospital
Nanjing, China
Site recruitment: Not reported
Huashan Hospital Fudan University
Shanghai, China
Site recruitment: Not reported
The Second Hospital of Hebei Medical University
Shijiazhuang, China
Site recruitment: Not reported
Tianjin Medical University General Hospital
Tianjin, China
Site recruitment: Not reported
Tongji Medical College Huazhong University of Science & Technology
Wuhan, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 18:18 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 3CompletedINTERVENTIONAL

Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients

ClinicalTrials.gov · NCT00210457 · Registry updated: 2020-03-31

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: France · Switzerland
Registry dates and results: Start: 2000-09. Completion: 2002-07-15 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (Autogel formulation) (drug)

Where the study takes place — 17 listed sites

Hôpital Sud
Amiens, France
Site recruitment: Not reported
Chu d'Angers
Angers, France
Site recruitment: Not reported
Hôpital de Bois Guillaume
Bois-Guillaume, France
Site recruitment: Not reported
Chu de la Cote de Nacre
Caen, France
Site recruitment: Not reported
Hôpital du Bocage
Dijon, France
Site recruitment: Not reported
Chu de Bicêtre
Le Kremlin-Bicêtre, France
Site recruitment: Not reported
Hôpital du Cluzeau
Limoges, France
Site recruitment: Not reported
Hôpital Neurologique
Lyon, France
Site recruitment: Not reported
Hôpital Lapeyronie
Montpellier, France
Site recruitment: Not reported
Hôpital de l'Archet 1
Nice, France
Site recruitment: Not reported
Hôpital du Haut-Levêque
Pessac, France
Site recruitment: Not reported
Hôpital Maison Blanche
Reims, France
Site recruitment: Not reported
Hôpital Sud
Rennes, France
Site recruitment: Not reported
Hôpital Bellevue
Saint-Etienne, France
Site recruitment: Not reported
Hôpital de Hautepierre
Strasbourg, France
Site recruitment: Not reported
Hôpital de Rangueil
Toulouse, France
Site recruitment: Not reported
Centre Hospitalier Vaudois
Lausanne, Switzerland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3WithdrawnINTERVENTIONAL

Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome

ClinicalTrials.gov · NCT04065165 · Registry updated: 2020-02-05

Condition / research focus: Small Intestinal NET; Carcinoid Heart Disease
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Countries with listed sites: No country reported
Registry dates and results: Start: 2020-04. Completion: 2027-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Telotristat Ethyl (drug) — also listed as: Xermelo
Lanreotide (drug) — also listed as: Somatuline

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Microbiotic Analysis in Digestive Endocrine Tumors

ClinicalTrials.gov · NCT04198402 · Registry updated: 2019-12-13

Condition / research focus: Digestive Neuroendocrine Tumor; Fecal Microbiota; Bacterial Signature
Sponsor: Assistance Publique - Hôpitaux de Paris
Countries with listed sites: No country reported
Registry dates and results: Start: 2020-01. Completion: 2023-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Biological sampling (biological)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Somatuline Autogel Preference and Health Economy Study

ClinicalTrials.gov · NCT00681187 · Registry updated: 2019-11-22

Condition / research focus: Neuroendocrine Tumour With Carcinoid Symptoms
Sponsor: Ipsen
Countries with listed sites: Denmark · Norway · Sweden
Registry dates and results: Start: 2008-06. Completion: 2010-08 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

lanreotide (Autogel formulation) (drug)

Where the study takes place — 10 listed sites

Aarhus University Hospital / Medisinsk afd. V
Aarhus, Denmark
Site recruitment: Not reported
Odense Univeristy Hospital / S-AMB
Odense, Denmark
Site recruitment: Not reported
Haukeland University Hospital / Kreftafd
Bergen, Norway
Site recruitment: Not reported
University Hospital North-Norway / GastroLab
Tromsø, Norway
Site recruitment: Not reported
S:t Olavs Hospital / Medisinsk Afd
Trondheim, Norway
Site recruitment: Not reported
Sahlgrenska University Hospital / Kirurgkliniken
Gothenburg, Sweden
Site recruitment: Not reported
Linköping University Hospital / Onkologen
Linköping, Sweden
Site recruitment: Not reported
Karolinska University Hospital, Huddinge / GastroCentrum Medicin
Stockholm, Sweden
Site recruitment: Not reported
Karolinska University Hospital, Solna / Kirurgmottagningen
Stockholm, Sweden
Site recruitment: Not reported
Akademiska Hospital/ Kliniken f onkologisk endokrinologi
Uppsala, Sweden
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3TerminatedINTERVENTIONAL

Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients

ClinicalTrials.gov · NCT01313273 · Registry updated: 2019-11-22

Condition / research focus: Prostate Cancer
Sponsor: Ipsen
Countries with listed sites: Italy
Registry dates and results: Start: 2011-06. Completion: 2013-06 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide, non steroidal anti androgens and LHRH-a (drug)
Non steroidal anti androgens and LHRH-a (drug)

Where the study takes place — 1 listed sites

A.O. S. Luigi Gonzaga
Orbassano ( TO), Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

Quality of Life in Patients With Inoperable Malignant Bowel Obstruction

ClinicalTrials.gov · NCT02365584 · Registry updated: 2019-11-22

Condition / research focus: Intestinal Obstruction
Sponsor: Ipsen
Countries with listed sites: Italy
Registry dates and results: Start: 2015-01. Completion: 2018-01-16 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

lanreotide (Autogel formulation) (drug)

Where the study takes place — 13 listed sites

Ospedale Sacro Cuore di Gesù, U.O.C. Oncologia Medica
Gallipoli, Lecce, Italy
Site recruitment: Not reported
Ospedali riuniti Ancona- Dipartimento Medicina Interna - Clinica Oncologica
Ancona, Italy
Site recruitment: Not reported
Centro di Riferimento Oncologico - di Aviano, Dip. di Oncologia Chirurgica- S.O.C. di Chirurgia Oncologica Generale
Aviano, Italy
Site recruitment: Not reported
Istituto Tumori "Giovanni Paolo II"- Istituto di Ricovero e Cura a Carattere Scientifico, U.O.C. DI ONCOLOGIA MEDICA
Bari, Italy
Site recruitment: Not reported
Ospedale Sacro Cuore di Gesù - Fatebenefratelli
Benevento, Italy
Site recruitment: Not reported
Hospice Convento delle Oblate
Florence, Italy
Site recruitment: Not reported
Azienda Sanitaria Locale n ° 5 "Spezzino" Ospedale Felettino - Oncologia Via del Forno 4
La Spezia, Italy
Site recruitment: Not reported
I.R.C.C.S. Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori (I.R.S.T.) srl
Meldola, Italy
Site recruitment: Not reported
Ospedale San Raffaele IRCCS, Ginecologia oncologica
Milan, Italy
Site recruitment: Not reported
Fondazione IRCCS Istituto Nazionale dei Tumori - Struttura Complessa di Cure Palliative, Terapia del Dolore e Riabilitazione
Milan, Italy
Site recruitment: Not reported
Azienda Ospedaliero - Polo Universitario "Luigi Sacco"
Milan, Italy
Site recruitment: Not reported
A.R.N.A.S. P.O. Civico Benfratelli - Oncologia Medica
Palermo, Italy
Site recruitment: Not reported
Azienda Ospedaliera Regionale San Carlo- Oncologia Medica
Potenza, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly

ClinicalTrials.gov · NCT00444873 · Registry updated: 2019-11-22

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: Germany
Registry dates and results: Start: 2005-01. Completion: 2008-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval (drug)

Where the study takes place — 1 listed sites

Klinikum Innenstadt
Munich, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

ClinicalTrials.gov · NCT00216398 · Registry updated: 2019-08-16

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: Australia
Registry dates and results: Start: 2004-06. Completion: 2006-06-22 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (Autogel formulation) (drug)

Where the study takes place — 1 listed sites

Westmead Hospital
Westmead, New South Wales, Australia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Somatuline Autogel: Acromegaly Self/Partner Injection Study

ClinicalTrials.gov · NCT00149188 · Registry updated: 2019-08-05

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2004-02. Completion: 2005-08-24 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (Autogel formulation) (drug)

Where the study takes place — 10 listed sites

Michael White Centre Diabetes & Endocrinology, Hull Royal Infirmary
Hull, East Yorkshire, United Kingdom
Site recruitment: Not reported
Department of Endocrinology, The Royal Free Hospital
Hampstead, London, United Kingdom
Site recruitment: Not reported
Dept of Endocrinology, Aberdeen Royal Infirmary
Aberdeen, United Kingdom
Site recruitment: Not reported
Department of Medicine, Queen Elizabeth Hospital
Birmingham, United Kingdom
Site recruitment: Not reported
Department of Endocrinology, Coventry & Warwickshire Hospital
Coventry, United Kingdom
Site recruitment: Not reported
Department of Endocrinology, Leicester Royal Infirmary
Leicester, United Kingdom
Site recruitment: Not reported
Department of Endocrinology, Manchester Royal Infirmary
Manchester, United Kingdom
Site recruitment: Not reported
The Oxford Centre for Diabetes, Endocrinology and Metabolism, The Churcill Hospital
Oxford, United Kingdom
Site recruitment: Not reported
Department of Endocrinology, Royal Hallamshire Hospital
Sheffield, United Kingdom
Site recruitment: Not reported
Department of Endocrinology, Sunderland Royal Hospital
Sunderland, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2WithdrawnINTERVENTIONAL

Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)

ClinicalTrials.gov · NCT00517491 · Registry updated: 2019-08-05

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: Mexico
Registry dates and results: Start: 2008-05. Completion: 2008-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

lanreotide (Autogel formulation) (drug)

Where the study takes place — 1 listed sites

Centro Médico Nacional Siglo XXI, IMSS
Mexico City, Mexico
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects

ClinicalTrials.gov · NCT02807233 · Registry updated: 2019-08-05

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: Portugal · Spain
Registry dates and results: Start: 2016-07. Completion: 2017-09 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 39 listed sites

Hospital de Santa Maria
Lisbon, Portugal
Site recruitment: Not reported
Centro Hospitalar Sao Jöao
Porto, Portugal
Site recruitment: Not reported
Hospital Univ. Nuestra Sra. Candelaria
Santa Cruz, Tenerife, Spain
Site recruitment: Not reported
Complejo Hospitalario Univ. A Coruña
A Coruña, Spain
Site recruitment: Not reported
Hospital Univ. Príncipe de Asturias
Alcalá de Henares, Spain
Site recruitment: Not reported
Hospital General Univ. de Alicante
Alicante, Spain
Site recruitment: Not reported
Hospital Univ. La Ribera
Alzira, Spain
Site recruitment: Not reported
Hospital Infanta Cristina
Badajoz, Spain
Site recruitment: Not reported
Hospital Cruces
Barakaldo, Spain
Site recruitment: Not reported
Hospital Puerta del Mar
Cadiz, Spain
Site recruitment: Not reported
Hospital Ciudad Real
Ciudad Real, Spain
Site recruitment: Not reported
Hospital Reina Sofía
Córdoba, Spain
Site recruitment: Not reported
Hospital de Getafe
Getafe, Spain
Site recruitment: Not reported
Hospital Univ. Girona Dr. Josep Trueta
Girona, Spain
Site recruitment: Not reported
Hospital de Jaén
Jaén, Spain
Site recruitment: Not reported
Hospital Bellvitge
L'Hospitalet de Llobregat, Spain
Site recruitment: Not reported
Hospital Univ. León
León, Spain
Site recruitment: Not reported
Hospital Arnau de Vilanova
Lleida, Spain
Site recruitment: Not reported
Hospital La Princesa
Madrid, Spain
Site recruitment: Not reported
Hospital Gregorio Marañón
Madrid, Spain
Site recruitment: Not reported
Hospital La Paz
Madrid, Spain
Site recruitment: Not reported
Hospital Univv. La Paz
Madrid, Spain
Site recruitment: Not reported
Hospital Puerta del Hierro
Madrid, Spain
Site recruitment: Not reported
Hospital Civil de Málaga
Málaga, Spain
Site recruitment: Not reported
Hospital Virgen de la Victoria
Málaga, Spain
Site recruitment: Not reported
Hospital Univ. Central de Asturias
Oviedo, Spain
Site recruitment: Not reported
Hospital Univ. Son Espases
Palma, Spain
Site recruitment: Not reported
Corporacio Sanitaria Parc Tauli
Sabadell, Spain
Site recruitment: Not reported
Hospital Infanta Sofía
San Sebastián de los Reyes, Spain
Site recruitment: Not reported
Hospital Clínico Univ. Santiago
Santiago de Compostela, Spain
Site recruitment: Not reported
Hospital Virgen del Rocío
Seville, Spain
Site recruitment: Not reported
Hospital Univ. Alava
Terrassa, Spain
Site recruitment: Not reported
Hospital Univ. Mutua de Terrassa
Terrassa, Spain
Site recruitment: Not reported
Hospital Obispo Polanco
Teruel, Spain
Site recruitment: Not reported
Hospital Virgen de la Salud
Toledo, Spain
Site recruitment: Not reported
Hospital Clínico de Valencia
Valencia, Spain
Site recruitment: Not reported
Hospital Univ. La Fe
Valencia, Spain
Site recruitment: Not reported
Hospital Clínico Univ. Valladolid
Valladolid, Spain
Site recruitment: Not reported
Hospital Miguel Servet
Zaragoza, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3CompletedINTERVENTIONAL

Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly

ClinicalTrials.gov · NCT00234572 · Registry updated: 2019-08-02

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: Czechia · France · Germany · Hong Kong · Hungary · Netherlands · United Kingdom · United States
Registry dates and results: Start: 2000-05. Completion: 2003-01-03 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (Autogel formulation) (drug)

Where the study takes place — 29 listed sites

Baptist Health System Inc
Birmingham, Alabama, United States
Site recruitment: Not reported
Pituitary Center
Los Angeles, California, United States
Site recruitment: Not reported
Northwestern Medical Facility
Chicago, Illinois, United States
Site recruitment: Not reported
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
Site recruitment: Not reported
Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported
University of Michigan Medical Center
Ann Arbor, Michigan, United States
Site recruitment: Not reported
New York University Medical Center
New York, New York, United States
Site recruitment: Not reported
University of Cincinnati
Cincinnati, Ohio, United States
Site recruitment: Not reported
Oregon Health Sciences University
Portland, Oregon, United States
Site recruitment: Not reported
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Ben Taub Hospital
Houston, Texas, United States
Site recruitment: Not reported
St Ann's Faculty Hospital
Brno, Czechia
Site recruitment: Not reported
University Hospital Charles University
Hradec Králové, Czechia
Site recruitment: Not reported
Charles University
Prague, Czechia
Site recruitment: Not reported
Clinique Marc Linquette
Lille, France
Site recruitment: Not reported
Hôpital Lariboisière - Service de Médecine B
Paris, France
Site recruitment: Not reported
Hôpital Cochin - Service d'Endocrinologie
Paris, France
Site recruitment: Not reported
CHRU de Brabois
Vandœuvre-lès-Nancy, France
Site recruitment: Not reported
Universitätklinikum Charité
Berlin, Germany
Site recruitment: Not reported
Med. Klinik der Universitätat Essen
Essen, Germany
Site recruitment: Not reported
Medizinische Klinik Innenstadt
München, Germany
Site recruitment: Not reported
Queen Mary Hospital
Pokfulam, Hong Kong
Site recruitment: Not reported
Semmelweiss University Medical School
Budapest, Hungary
Site recruitment: Not reported
Semmelweiss University
Budapest, Hungary
Site recruitment: Not reported
Academic Hospital Leiden
Leiden, Netherlands
Site recruitment: Not reported
Academic Hospital Rotterdam
Rotterdam, Netherlands
Site recruitment: Not reported
Queen Elizabeth Hospital
Edgbaston, Birmingham, United Kingdom
Site recruitment: Not reported
The Royal Free Hospital
Hampstead, London, United Kingdom
Site recruitment: Not reported
Christie Hospital
Manchester, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide

ClinicalTrials.gov · NCT00234520 · Registry updated: 2019-08-02

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: Belgium · Czechia · Denmark · France · Hungary · Italy · Poland · Spain · Sweden · United Kingdom
Registry dates and results: Start: 2003-05. Completion: 2005-02-18 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 33 listed sites

Cliniques Universitaires Saint Luc
Brussels, Belgium
Site recruitment: Not reported
UZ Gasthuisberg
Leuven, Belgium
Site recruitment: Not reported
CHU de Liege
Liège, Belgium
Site recruitment: Not reported
University Hospital, Charles University
Kralove, Czechia
Site recruitment: Not reported
1st School of Medicine, Charles University
Prague, Czechia
Site recruitment: Not reported
National University Hospital
Copenhagen, Denmark
Site recruitment: Not reported
Hôpital de Bois
Bois-Guillaume, France
Site recruitment: Not reported
Hôpital de la Timone
Marseille, France
Site recruitment: Not reported
CHU de Brabois
Nancy, France
Site recruitment: Not reported
Centre Hospitalier Régional d'Orléans
Orléans, France
Site recruitment: Not reported
Hôpital du Haut-Lévêque
Pessac, France
Site recruitment: Not reported
Hôpital Maison Blanche
Reims, France
Site recruitment: Not reported
CHU de Rangueil
Toulouse, France
Site recruitment: Not reported
Semmelweis University Medical School
Budapest, Hungary
Site recruitment: Not reported
National Medical Center
Budapest, Hungary
Site recruitment: Not reported
Ospedali Riuniti di Bergamo
Bergamo, Italy
Site recruitment: Not reported
Università degli Studi di Ferrara
Ferrara, Italy
Site recruitment: Not reported
Dipartimento di Scienze, Endocrinologiche e Metaboliche
Genova, Italy
Site recruitment: Not reported
Università degli Studi di Milano
Milan, Italy
Site recruitment: Not reported
University "Federico II" of Naples
Naples, Italy
Site recruitment: Not reported
Clinica Medica II
Roma, Italy
Site recruitment: Not reported
Bielanski Hospital
Warsaw, Poland
Site recruitment: Not reported
Hospital General de Alicante
Alicante, Spain
Site recruitment: Not reported
Clínica Puerta de Hierro
Madrid, Spain
Site recruitment: Not reported
Fundación Jiménez Díaz
Madrid, Spain
Site recruitment: Not reported
Research Centre for Endocrinology and Metabolism
Gothenburg, Sweden
Site recruitment: Not reported
Endokrinologiska kliniken
Malmö, Sweden
Site recruitment: Not reported
Karolinska Sjukhuset
Stockholm, Sweden
Site recruitment: Not reported
Queen Elizabeth Medical Centre
Edgbaston, Birmingham, United Kingdom
Site recruitment: Not reported
Royal Free Hospital
Hampstead, United Kingdom
Site recruitment: Not reported
Michael White Diabetes Centre
Hull, United Kingdom
Site recruitment: Not reported
Christie Hospital
Manchester, United Kingdom
Site recruitment: Not reported
Northern General Hospital
Sheffield, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients

ClinicalTrials.gov · NCT02075606 · Registry updated: 2019-06-07

Condition / research focus: NeuroEndocrine Tumours
Sponsor: Ipsen
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2014-05. Completion: 2017-06 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

lanreotide acetate (drug)

Where the study takes place — 14 listed sites

Basingstoke & North Hampshire Hospital
Basingstoke, United Kingdom
Site recruitment: Not reported
Queen Elizabeth Hospital
Birmingham, United Kingdom
Site recruitment: Not reported
University Hospital Wales
Cardiff, United Kingdom
Site recruitment: Not reported
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
Site recruitment: Not reported
St James's University Hospital
Leeds, United Kingdom
Site recruitment: Not reported
University Hospital Aintree
Liverpool, United Kingdom
Site recruitment: Not reported
Hammersmith Hospital
London, United Kingdom
Site recruitment: Not reported
King's College Hospital
London, United Kingdom
Site recruitment: Not reported
Royal Free Hospital
London, United Kingdom
Site recruitment: Not reported
Maidstone Hospital
Maidstone, United Kingdom
Site recruitment: Not reported
The Christie Hospital
Manchester, United Kingdom
Site recruitment: Not reported
Norfolk & Norwich Hospital
Norwich, United Kingdom
Site recruitment: Not reported
Royal Hallamshire Hospital
Sheffield, United Kingdom
Site recruitment: Not reported
Southampton University Hospital
Southampton, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET

ClinicalTrials.gov · NCT03083210 · Registry updated: 2019-05-20

Condition / research focus: Neuroendocrine Tumors
Sponsor: Samsung Medical Center
Countries with listed sites: South Korea
Registry dates and results: Start: 2017-07-05. Completion: 2020-02 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (drug)

Where the study takes place — 1 listed sites

Youngsuk Park
Seoul, South Korea
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET

ClinicalTrials.gov · NCT02231762 · Registry updated: 2019-05-06

Condition / research focus: Gastroenteropancreatic Neuroendocrine Tumors
Sponsor: Ipsen
Countries with listed sites: Austria · Germany
Registry dates and results: Start: 2014-10. Completion: 2017-06 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide Autogel 120 mg (drug)
Temozolomide (TMZ) (drug)

Where the study takes place — 10 listed sites

Vienna General Hospital
Vienna, Austria
Site recruitment: Not reported
Zentralklinik Bad Berka
Bad Berka, Germany
Site recruitment: Not reported
Charité University Hospital
Berlin, Germany
Site recruitment: Not reported
University Hospital Essen
Essen, Germany
Site recruitment: Not reported
ENDOC Hamburg
Hamburg, Germany
Site recruitment: Not reported
Oncological Center Leer
Leer, Germany
Site recruitment: Not reported
University Hospital Mainz
Mainz, Germany
Site recruitment: Not reported
University Hospital Mannheim
Mannheim, Germany
Site recruitment: Not reported
University Hospital Marburg
Marburg, Germany
Site recruitment: Not reported
University Hospital Munich
Munich, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

ClinicalTrials.gov · NCT02396953 · Registry updated: 2019-04-25

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: Belgium · Czechia · France · Germany · Italy · Lithuania · Netherlands · Poland · Romania · Russia · Spain · United Kingdom
Registry dates and results: Start: 2015-03. Completion: 2017-11-28 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide PRF (drug) — also listed as: Lanreotide acetate

Where the study takes place — 36 listed sites

Antwerp University Hospital
Edegem, Belgium
Site recruitment: Not reported
Domaine Universitaire Sart Tilman
Liège, Belgium
Site recruitment: Not reported
Fakultni nemocnice u sv. Anny v Brne
Brno, Czechia
Site recruitment: Not reported
Fakultní nemocnice Hradec Králové (University Hospital Hradec)
Hradec Králové, Czechia
Site recruitment: Not reported
CHU le BOCAGE
Dijon, France
Site recruitment: Not reported
Hôpital de Bicêtre (AP-HP)
Le Kremlin-Bicêtre, France
Site recruitment: Not reported
CHU de la Timone
Marseille, France
Site recruitment: Not reported
Hôpital Haut Lévêque
Pessac, France
Site recruitment: Not reported
University Medicine Berlin
Berlin, Germany
Site recruitment: Not reported
University Medical Center Hamburg-Eppendorf
Hamburg, Germany
Site recruitment: Not reported
IRCCS AOU San Martino-IST, University of Genova
Genova, Italy
Site recruitment: Not reported
Azienda Ospedaliera Padova
Padova, Italy
Site recruitment: Not reported
Policlinico of Palermo
Palermo, Italy
Site recruitment: Not reported
Ospedale Cisanello
Pisa, Italy
Site recruitment: Not reported
Azienda Ospedaliera Universitaria Senese
Siena, Italy
Site recruitment: Not reported
AO Città della Salute e della Scienza di Torino
Torino, Italy
Site recruitment: Not reported
Lithuanian University of Health Sciences (LUHS) Kauno klinikos
Kaunas, Lithuania
Site recruitment: Not reported
Vilnius University hospital Santariskiu Klinikos
Vilnius, Lithuania
Site recruitment: Not reported
Erasmus University Medical Centre Rotterdam
Rotterdam, Netherlands
Site recruitment: Not reported
Uniwersytecki Szpital Kliniczny w Białymstoku
Bialystok, Poland
Site recruitment: Not reported
Szpital Kliniczny im. H. Święcickiego UM w Poznaniu
Poznan, Poland
Site recruitment: Not reported
Szpital Bielanski im. ks. Jerzego Popieluszki SPZOZ
Warsaw, Poland
Site recruitment: Not reported
Szpital Kliniczny nr 1
Wroclaw, Poland
Site recruitment: Not reported
National Institute of Endocrinology
Bucharest, Romania
Site recruitment: Not reported
Kazan state Medical Academy
Kazan', Russia
Site recruitment: Not reported
Kemerovo Regional Clinical Hospital
Kemerovo, Russia
Site recruitment: Not reported
Endocrinological Research Center Ministry of Health Russian Federation
Moscow, Russia
Site recruitment: Not reported
Healthcare Institution
Nizhny Novgorod, Russia
Site recruitment: Not reported
Federal State Budgetary Military
Saint Petersburg, Russia
Site recruitment: Not reported
North-Western State Medical University
Saint Petersburg, Russia
Site recruitment: Not reported
Hospital Universitario Vall d' Hebron
Barcelona, Spain
Site recruitment: Not reported
Hospital Ramon y Cajal
Madrid, Spain
Site recruitment: Not reported
Hospital Universitario Virgen del Rocio
Seville, Spain
Site recruitment: Not reported
Queen Mary, University of London
London, United Kingdom
Site recruitment: Not reported
Christie NHS Foundation Trust
Manchester, United Kingdom
Site recruitment: Not reported
Churchill Hospital
Oxford, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction

ClinicalTrials.gov · NCT02275338 · Registry updated: 2019-04-16

Condition / research focus: Intestinal Obstruction
Sponsor: Ipsen
Countries with listed sites: Belgium
Registry dates and results: Start: 2014-11-19. Completion: 2017-11-09 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide Autogel (drug) — also listed as: Somatuline Autogel

Where the study takes place — 17 listed sites

Facility not reported
Aalst, Belgium
Site recruitment: Not reported
Facility not reported
Antwerp, Belgium
Site recruitment: Not reported
Facility not reported
Bruges, Belgium
Site recruitment: Not reported
Ste-Elisabeth Hospital
Brussels, Belgium
Site recruitment: Not reported
Facility not reported
Chimay, Belgium
Site recruitment: Not reported
Facility not reported
Ghent, Belgium
Site recruitment: Not reported
Facility not reported
Haine-Saint-Paul, Belgium
Site recruitment: Not reported
Facility not reported
Libramont, Belgium
Site recruitment: Not reported
Facility not reported
Liège, Belgium
Site recruitment: Not reported
Facility not reported
Mons, Belgium
Site recruitment: Not reported
Facility not reported
Montigny-le-Tilleul, Belgium
Site recruitment: Not reported
Facility not reported
Ostend, Belgium
Site recruitment: Not reported
Facility not reported
Ottignies, Belgium
Site recruitment: Not reported
Facility not reported
Sint-Niklaas, Belgium
Site recruitment: Not reported
Facility not reported
Tournai, Belgium
Site recruitment: Not reported
Facility not reported
Verviers, Belgium
Site recruitment: Not reported
Facility not reported
Yvoir, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae

ClinicalTrials.gov · NCT00729313 · Registry updated: 2019-03-04

Condition / research focus: Digestive Fistulae
Sponsor: Ipsen
Countries with listed sites: France · Russia
Registry dates and results: Start: 2000-04. Completion: 2005-04 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide microparticles (drug)
Placebo (drug)

Where the study takes place — 19 listed sites

Hôpital Nord
Amiens, France
Site recruitment: Not reported
CHU J. Minjoz
Besançon, France
Site recruitment: Not reported
Hôpital Avicenne
Bobigny, France
Site recruitment: Not reported
Hôpital de la Cavale Blanche
Brest, France
Site recruitment: Not reported
Hôpital Louis Mourier
Colombes, France
Site recruitment: Not reported
Hôpital Henri Mondor
Créteil, France
Site recruitment: Not reported
Hôpital A. Michallon
Grenoble, France
Site recruitment: Not reported
CHU de Bicêtre
Le Kremlin-Bicêtre, France
Site recruitment: Not reported
Hôpital Edouard Herriot
Lyon, France
Site recruitment: Not reported
Hotel Dieu
Lyon, France
Site recruitment: Not reported
Hôpital Nord
Marseille, France
Site recruitment: Not reported
Hôpital Lariboisière
Paris, France
Site recruitment: Not reported
Groupe Hospitalier Pitié-Salpêtrière
Paris, France
Site recruitment: Not reported
Hôpital Pontchaillou
Rennes, France
Site recruitment: Not reported
Hôpital de Hautepierre
Strasbourg, France
Site recruitment: Not reported
Hôpital Trousseau
Tours, France
Site recruitment: Not reported
Hôpital de Brabois
Vandœuvre-lès-Nancy, France
Site recruitment: Not reported
Institute of Surgery n.a. A.V. Vishnevsky
Moscow, Russia
Site recruitment: Not reported
National Research Centre of Surgery
Moscow, Russia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly

ClinicalTrials.gov · NCT02493517 · Registry updated: 2019-01-29

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: China
Registry dates and results: Start: 2014-10. Completion: 2017-02-16 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide Autogel® (drug)
Lanreotide Acetate (drug)

Where the study takes place — 10 listed sites

Peking Union Medical College Hospital
Beijing, China
Site recruitment: Not reported
West China Hospital, Sichuan University
Chengdu, China
Site recruitment: Not reported
Fujian Provincial Hospital
Fuzhou, China
Site recruitment: Not reported
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, China
Site recruitment: Not reported
Affiliate Hospital of Guiyang Medical College
Guizhou, China
Site recruitment: Not reported
Jiangsu Provincial People's Hospital
Nanjing, China
Site recruitment: Not reported
Huashan Hospital Fudan University
Shanghai, China
Site recruitment: Not reported
The Second Hospital of Hebei Medical University
Shijiazhuang, China
Site recruitment: Not reported
Tianjin Medical University General Hospital
Tianjin, China
Site recruitment: Not reported
Tongji Medical College Huazhong University of Science & Technology
Wuhan, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →